Cargando…

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the manag...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Nannan, Yang, Yan, Jin, Dongdong, Zhang, Zhenan, Shen, Ke, Yang, Jing, Chen, Huanhuan, Zhao, Xinyue, Yang, Li, Lu, Huaiwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455597/
https://www.ncbi.nlm.nih.gov/pubmed/36091750
http://dx.doi.org/10.3389/fphar.2022.967633
_version_ 1784785614084767744
author Wang, Nannan
Yang, Yan
Jin, Dongdong
Zhang, Zhenan
Shen, Ke
Yang, Jing
Chen, Huanhuan
Zhao, Xinyue
Yang, Li
Lu, Huaiwu
author_facet Wang, Nannan
Yang, Yan
Jin, Dongdong
Zhang, Zhenan
Shen, Ke
Yang, Jing
Chen, Huanhuan
Zhao, Xinyue
Yang, Li
Lu, Huaiwu
author_sort Wang, Nannan
collection PubMed
description Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients.
format Online
Article
Text
id pubmed-9455597
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94555972022-09-09 PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies Wang, Nannan Yang, Yan Jin, Dongdong Zhang, Zhenan Shen, Ke Yang, Jing Chen, Huanhuan Zhao, Xinyue Yang, Li Lu, Huaiwu Front Pharmacol Pharmacology Breast cancer and gynecological tumors seriously endanger women’s physical and mental health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and radiotherapy, the prognosis and overall survival of cancer patients have improved compared to earlier, but the management of advanced disease still faces great challenges. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been clinically approved for breast and gynecological cancer patients, significantly improving their quality of life, especially of patients with BRCA1/2 mutations. However, drug resistance faced by PARPi therapy has hindered its clinical promotion. Therefore, developing new drug strategies to resensitize cancers affecting women to PARPi therapy is the direction of our future research. Currently, the effects of PARPi in combination with other drugs to overcome drug resistance are being studied. In this article, we review the mechanisms of PARPi resistance and summarize the current combination of clinical trials that can improve its resistance, with a view to identify the best clinical treatment to save the lives of patients. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9455597/ /pubmed/36091750 http://dx.doi.org/10.3389/fphar.2022.967633 Text en Copyright © 2022 Wang, Yang, Jin, Zhang, Shen, Yang, Chen, Zhao, Yang and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Nannan
Yang, Yan
Jin, Dongdong
Zhang, Zhenan
Shen, Ke
Yang, Jing
Chen, Huanhuan
Zhao, Xinyue
Yang, Li
Lu, Huaiwu
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title_full PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title_fullStr PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title_full_unstemmed PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title_short PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
title_sort parp inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455597/
https://www.ncbi.nlm.nih.gov/pubmed/36091750
http://dx.doi.org/10.3389/fphar.2022.967633
work_keys_str_mv AT wangnannan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT yangyan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT jindongdong parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT zhangzhenan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT shenke parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT yangjing parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT chenhuanhuan parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT zhaoxinyue parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT yangli parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies
AT luhuaiwu parpinhibitorresistanceinbreastandgynecologicalcancerresistancemechanismsandcombinationtherapystrategies